Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Daxor Corp Wins Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program

Author: Benzinga Newsdesk | October 04, 2023 08:04am

Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it has been accepted into the National Institutes of Health (NIH) Catalyze Preclinical Services Program. This program supports preclinical development, including studies and activities needed to meet the regulatory requirements for therapeutic and device submissions of technologies relevant to the National Heart, Lung, and Blood Institute (NHLBI)'s mission. This effort will be done in collaboration with two nationally recognized contract research organizations, to support the continued development of Daxor's non-nuclear fluorescent blood volume analyzer (BVA) device.

Posted In: DXR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)
CORE Finalist